Strategies in the development of vaccines to prevent infections with group A streptococcus

References

• Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685 - 94; http://dx.doi.org/10.1016/S1473-3099(05)70267-X; PMID: 16253886
   PubMed Web of Science ®Google Scholar
• McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infect Dis 2004; 4:240 - 5; http://dx.doi.org/10.1016/S1473-3099(04)00975-2; PMID: 15050943
   PubMed Web of Science ®Google Scholar
• Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969; 207:1115 - 9; http://dx.doi.org/10.1001/jama.1969.03150190037007; PMID: 5818242
   PubMed Web of Science ®Google Scholar
• D’Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978; 138:712 - 8; http://dx.doi.org/10.1093/infdis/138.6.712; PMID: 368261
   PubMed Web of Science ®Google Scholar
• Fox EN, Waldman RH, Wittner MK, Mauceri AA, Dorfman A. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest 1973; 52:1885 - 92; http://dx.doi.org/10.1172/JCI107372; PMID: 4719668
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. Revocation of status of specific products; Group A streptococcus. Direct final rule. Fed Regist 2005; 70:72197 - 9; PMID: 16323338
   PubMedGoogle Scholar
• Food and Drug Administration, HHS. Revocation of status of specific products; Group A streptococcus. Direct final rule. Fed Regist 2005; 70:72197 - 9; PMID: 16323338
   PubMedGoogle Scholar
• Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2:285 - 314; PMID: 2670192
   PubMed Web of Science ®Google Scholar
• Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health 2007; 43:203 - 13; http://dx.doi.org/10.1111/j.1440-1754.2007.01051.x; PMID: 17444820
   PubMed Web of Science ®Google Scholar
• Smeesters PR, Mardulyn P, Vergison A, Leplae R, Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008; 26:5835 - 42; http://dx.doi.org/10.1016/j.vaccine.2008.08.037; PMID: 18789365
   PubMed Web of Science ®Google Scholar
• Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 2011; 29:8175 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.09.005; PMID: 21920403
   PubMed Web of Science ®Google Scholar
• Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171:1576 - 85; http://dx.doi.org/10.1093/infdis/171.6.1576; PMID: 7769295
   PubMed Web of Science ®Google Scholar
• Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005; 12:833 - 6; PMID: 16002631
   PubMedGoogle Scholar
• Brandt ER, Hayman WA, Currie B, Pruksakorn S, Good MF. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997; 15:1805 - 12; http://dx.doi.org/10.1016/S0264-410X(97)00178-3; PMID: 9364687
   PubMed Web of Science ®Google Scholar
• Ji YD, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65:2080 - 7; PMID: 9169735
   PubMed Web of Science ®Google Scholar
• Zabriskie JB, Poon-King T, Blake MS, Michon F, Yoshinaga M. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol 1997; 418:917 - 9; PMID: 9331798
   PubMed Web of Science ®Google Scholar
• Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997; 9:1723 - 33; http://dx.doi.org/10.1093/intimm/9.11.1723; PMID: 9418133
   PubMed Web of Science ®Google Scholar
• Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 1994; 16:443 - 50; http://dx.doi.org/10.1006/mpat.1994.1044; PMID: 7830531
   PubMed Web of Science ®Google Scholar
• Shet A, Kaplan EL, Johnson DR, Cleary PP. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003; 188:809 - 17; http://dx.doi.org/10.1086/377700; PMID: 12964111
   PubMed Web of Science ®Google Scholar
• Valentin-Weigand P, Talay SR, Kaufhold A, Timmis KN, Chhatwal GS. The fibronectin binding domain of the Sfb protein adhesin of Streptococcus pyogenes occurs in many group A streptococci and does not cross-react with heart myosin. Microb Pathog 1994; 17:111 - 20; http://dx.doi.org/10.1006/mpat.1994.1057; PMID: 7861955
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24:191 - 7; http://dx.doi.org/10.1038/nbt1179; PMID: 16415855
   PubMed Web of Science ®Google Scholar
• Zhang S, Green NM, Sitkiewicz I, Lefebvre RB, Musser JM. Identification and characterization of an antigen I/II family protein produced by group A Streptococcus. Infect Immun 2006; 74:4200 - 13; http://dx.doi.org/10.1128/IAI.00493-06; PMID: 16790795
   PubMed Web of Science ®Google Scholar
• Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, et al. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med (Berl) 2012; 90:1197 - 207; http://dx.doi.org/10.1007/s00109-012-0897-9; PMID: 22527883
   PubMed Web of Science ®Google Scholar
• Chan AH, Tan HC, Chow AY, Lim AP, Lok SM, Moreland NJ, et al. A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein. PLoS One 2012; 7:e33451; http://dx.doi.org/10.1371/journal.pone.0033451; PMID: 22509258
   PubMed Web of Science ®Google Scholar
• Kelker HC, Itri VR, Valentine FT. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS One 2010; 5:e8555; http://dx.doi.org/10.1371/journal.pone.0008555; PMID: 20052405
   PubMed Web of Science ®Google Scholar
• Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol 1990; 145:1251 - 6; PMID: 1696296
   PubMed Web of Science ®Google Scholar
• Jones KF, Khan SA, Erickson BW, Hollingshead SK, Scott JR, Fischetti VA. Immunochemical localization and amino acid sequences of crossreactive epitopes within the group A streptococcal M6 protein. J Exp Med 1986; 164:1226 - 38; http://dx.doi.org/10.1084/jem.164.4.1226; PMID: 2428914
   PubMed Web of Science ®Google Scholar
• Miller L, Burdett V, Poirier TP, Gray LD, Beachey EH, Kehoe MA. Conservation of protective and nonprotective epitopes in M proteins of group A streptococci. Infect Immun 1988; 56:2198 - 204; PMID: 2456272
   PubMed Web of Science ®Google Scholar
• Lancefield RC. Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med 1957; 106:525 - 44; http://dx.doi.org/10.1084/jem.106.4.525; PMID: 13475611
   PubMed Web of Science ®Google Scholar
• Pruksakorn S, Galbraith A, Houghten RA, Good MF. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol 1992; 149:2729 - 35; PMID: 1383324
   PubMed Web of Science ®Google Scholar
• Crater DL, van de Rijn I. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 1995; 270:18452 - 8; http://dx.doi.org/10.1074/jbc.270.31.18452; PMID: 7629171
   PubMed Web of Science ®Google Scholar
• Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, et al. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 1994; 344:639 - 42; http://dx.doi.org/10.1016/S0140-6736(94)92083-4; PMID: 7520963
   PubMed Web of Science ®Google Scholar
• Brandt ER, Hayman WA, Currie B, Carapetis J, Wood Y, Jackson DC, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996; 89:331 - 7; http://dx.doi.org/10.1046/j.1365-2567.1996.d01-754.x; PMID: 8958044
   PubMed Web of Science ®Google Scholar
• Steer AC, Magor G, Jenney AWJ, Kado J, Good MF, McMillan D, et al. emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009; 47:2502 - 9; http://dx.doi.org/10.1128/JCM.00312-09; PMID: 19515838
   PubMed Web of Science ®Google Scholar
• Bauer MJ, Georgousakis MM, Vu T, Henningham A, Hofmann A, Rettel M, et al. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 2012; 30:2197 - 205; http://dx.doi.org/10.1016/j.vaccine.2011.12.115; PMID: 22265945
   PubMed Web of Science ®Google Scholar
• Martin DR, Sriprakash, K. S. Epidemiology of group A streptococcal disease in Australia and NewZealand. Recent advances in Microbiology 1996; 4:1-40.
   Google Scholar
• Dale JB, Beachey EH. Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med 1985; 161:113 - 22; http://dx.doi.org/10.1084/jem.161.1.113; PMID: 2578539
   PubMed Web of Science ®Google Scholar
• Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol 1989; 145:5 - 26; http://dx.doi.org/10.1007/978-3-642-74594-2_2; PMID: 2680297
   PubMed Web of Science ®Google Scholar
• Guilherme L, Oshiro SE, Faé KC, Cunha-Neto E, Renesto G, Goldberg AC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001; 69:5345 - 51; http://dx.doi.org/10.1128/IAI.69.9.5345-5351.2001; PMID: 11500404
   PubMed Web of Science ®Google Scholar
• Cunningham MW. T cell mimicry in inflammatory heart disease. Mol Immunol 2004; 40:1121 - 7; http://dx.doi.org/10.1016/j.molimm.2003.11.023; PMID: 15036918
   PubMed Web of Science ®Google Scholar
• Guilherme L, Cunha-Neto E, Tanaka AC, Dulphy N, Toubert A, Kalil J. Heart-directed autoimmunity: the case of rheumatic fever. J Autoimmun 2001; 16:363 - 7; http://dx.doi.org/10.1006/jaut.2000.0487; PMID: 11334505
   PubMed Web of Science ®Google Scholar
• Martins TB, Hoffman JL, Augustine NH, Phansalkar AR, Fischetti VA, Zabriskie JB, et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 2008; 20:445 - 52; http://dx.doi.org/10.1093/intimm/dxn004; PMID: 18245783
   PubMed Web of Science ®Google Scholar
• Goldstein I, Halpern B, Robert L. Immunological Relationship between Streptococcus a Polysaccharide and Structural Glycoproteins of Heart Valve. Nature 1967; 213:44; http://dx.doi.org/10.1038/213044a0
   Web of Science ®Google Scholar
• Guilherme L, Dulphy N, Douay C, Coelho V, Cunha-Neto E, Oshiro SE, et al. Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. Int Immunol 2000; 12:1063 - 74; http://dx.doi.org/10.1093/intimm/12.7.1063; PMID: 10882418
   PubMed Web of Science ®Google Scholar
• Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PM, Assis RV, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995; 92:415 - 20; http://dx.doi.org/10.1161/01.CIR.92.3.415; PMID: 7634457
   PubMed Web of Science ®Google Scholar
• Sampaio RO, Fae KC, Demarchi LM, Pomerantzeff PM, Aiello VD, Spina GS, et al. Rheumatic heart disease: 15 years of clinical and immunological follow-up. Vasc Health Risk Manag 2007; 3:1007 - 17; PMID: 18200819
   PubMedGoogle Scholar
• Pruksakorn S, Currie B, Brandt E, Phornphutkul C, Hunsakunachai S, Manmontri A, et al. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994; 6:1235 - 44; http://dx.doi.org/10.1093/intimm/6.8.1235; PMID: 7981150
   PubMed Web of Science ®Google Scholar
• Guilherme L, Cury P, Demarchi LMF, Coelho V, Abel L, Lopez AP, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 2004; 165:1583 - 91; http://dx.doi.org/10.1016/S0002-9440(10)63415-3; PMID: 15509528
   PubMed Web of Science ®Google Scholar
• Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, Pruksakorn S, et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res 1996; 9:12 - 20; PMID: 8727479
   PubMedGoogle Scholar
• Pandey M, Wykes MN, Hartas J, Good MF, Batzloff MR. Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J Immunol 2013; 190:2692 - 701; http://dx.doi.org/10.4049/jimmunol.1202333; PMID: 23401589
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598 - 608; http://dx.doi.org/10.1086/374800; PMID: 12721940
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 2005; 192:1450 - 5; http://dx.doi.org/10.1086/466528; PMID: 16170764
   PubMed Web of Science ®Google Scholar
• Batzloff MR, Hartas J, Zeng WG, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194:325 - 30; http://dx.doi.org/10.1086/505146; PMID: 16826480
   PubMed Web of Science ®Google Scholar